# Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

> **NCT06940141** · PHASE2 · RECRUITING · sponsor: **Connect Biopharm LLC** · enrollment: 160 (estimated)

## Conditions studied

- Asthma Acute

## Interventions

- **COMBINATION_PRODUCT:** Rademikibart in prefilled syringe
- **DRUG:** Matching placebo in prefilled syringe

## Key facts

- **NCT ID:** NCT06940141
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-08
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940141, "Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06940141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*